Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
Apellis Pharmaceuticals (Nasdaq: APLS) has scheduled its first quarter 2025 financial results conference call and webcast for May 7, 2025, at 8:30 a.m. ET. Investors can pre-register for the phone call, while a live audio webcast with accompanying slides will be available through the company's website under "Events and Presentations" in the "Investors and Media" section.
Apellis positions itself as a global biopharmaceutical leader that combines scientific innovation with patient care. The company has achieved significant milestones, including:
- Introduction of the first new complement medicine class in 15 years
- Two approved medicines targeting C3
- Development of the first-ever therapy for geographic atrophy, a major cause of blindness globally
The webcast replay will be accessible for 90 days after the event. Investor relations contact is available through Neil Carnahan.
Apellis Pharmaceuticals (Nasdaq: APLS) ha programmato la conference call e il webcast per la presentazione dei risultati finanziari del primo trimestre 2025 il 7 maggio 2025 alle 8:30 ET. Gli investitori possono registrarsi in anticipo per la chiamata telefonica, mentre un webcast audio in diretta con slide sarà disponibile sul sito web dell'azienda nella sezione "Eventi e Presentazioni" sotto "Investitori e Media".
Apellis si presenta come un leader globale biofarmaceutico che unisce innovazione scientifica e cura del paziente. L'azienda ha raggiunto traguardi importanti, tra cui:
- Introduzione della prima nuova classe di farmaci complementari in 15 anni
- Due medicinali approvati che agiscono sul C3
- Sviluppo della prima terapia per l'atrofia geografica, una delle principali cause di cecità a livello mondiale
La registrazione del webcast sarà disponibile per 90 giorni dopo l'evento. Il contatto per le relazioni con gli investitori è Neil Carnahan.
Apellis Pharmaceuticals (Nasdaq: APLS) ha programado su llamada y webcast para los resultados financieros del primer trimestre de 2025 el 7 de mayo de 2025 a las 8:30 a.m. ET. Los inversores pueden preinscribirse para la llamada telefónica, mientras que un webcast de audio en vivo con diapositivas estará disponible en el sitio web de la empresa en la sección "Eventos y Presentaciones" dentro de "Inversores y Medios".
Apellis se posiciona como un líder biofarmacéutico global que combina innovación científica con cuidado al paciente. La compañía ha alcanzado hitos importantes, entre ellos:
- Introducción de la primera nueva clase de medicamentos del complemento en 15 años
- Dos medicamentos aprobados que actúan sobre el C3
- Desarrollo de la primera terapia para la atrofia geográfica, una causa principal de ceguera a nivel mundial
La repetición del webcast estará disponible durante 90 días después del evento. El contacto de relaciones con inversores es Neil Carnahan.
Apellis Pharmaceuticals (나스닥: APLS)는 2025년 1분기 재무실적 컨퍼런스 콜 및 웹캐스트를 2025년 5월 7일 오전 8시 30분(동부시간)에 예정하고 있습니다. 투자자들은 전화 통화 사전 등록이 가능하며, 회사 웹사이트의 "투자자 및 미디어" 섹션 내 "이벤트 및 프레젠테이션"에서 실시간 오디오 웹캐스트와 슬라이드 자료를 이용할 수 있습니다.
Apellis는 과학적 혁신과 환자 치료를 결합한 글로벌 바이오제약 선도기업으로 자리매김하고 있습니다. 회사는 다음과 같은 주요 성과를 이루었습니다:
- 15년 만에 처음 선보인 새로운 보체 치료제 클래스 도입
- C3를 타깃으로 한 두 가지 승인된 약물
- 전 세계 실명의 주요 원인인 지리적 위축에 대한 최초의 치료제 개발
웹캐스트 재생은 행사 후 90일간 이용 가능하며, 투자자 관계 담당자는 Neil Carnahan입니다.
Apellis Pharmaceuticals (Nasdaq : APLS) a programmé sa conférence téléphonique et webcast pour les résultats financiers du premier trimestre 2025 le 7 mai 2025 à 8h30 ET. Les investisseurs peuvent s'inscrire à l'avance pour l'appel téléphonique, tandis qu'un webcast audio en direct accompagné de diapositives sera disponible sur le site internet de la société, dans la rubrique « Événements et présentations » de la section « Investisseurs et médias ».
Apellis se positionne comme un leader biopharmaceutique mondial alliant innovation scientifique et prise en charge des patients. L'entreprise a atteint des jalons importants, notamment :
- L'introduction de la première nouvelle classe de médicaments du complément en 15 ans
- Deux médicaments approuvés ciblant le C3
- Le développement de la toute première thérapie pour l’atrophie géographique, une cause majeure de cécité dans le monde
Le replay du webcast sera accessible pendant 90 jours après l'événement. Le contact des relations investisseurs est Neil Carnahan.
Apellis Pharmaceuticals (Nasdaq: APLS) hat seine Telefonkonferenz und Webcast zur Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 7. Mai 2025 um 8:30 Uhr ET geplant. Investoren können sich vorab für den Anruf registrieren, während ein Live-Audio-Webcast mit begleitenden Folien über die Website des Unternehmens unter "Veranstaltungen und Präsentationen" im Bereich "Investoren und Medien" verfügbar sein wird.
Apellis positioniert sich als globaler biopharmazeutischer Marktführer, der wissenschaftliche Innovation mit Patientenversorgung verbindet. Das Unternehmen hat bedeutende Meilensteine erreicht, darunter:
- Einführung der ersten neuen Komplement-Medikamentenklasse seit 15 Jahren
- Zwei zugelassene Medikamente, die auf C3 abzielen
- Entwicklung der allerersten Therapie für geografische Atrophie, eine Hauptursache für Erblindung weltweit
Die Wiederholung des Webcasts ist 90 Tage nach der Veranstaltung verfügbar. Ansprechpartner für Investor Relations ist Neil Carnahan.
- First-ever therapy for geographic atrophy approved and in market
- Two approved medicines targeting C3 in portfolio
- Pioneer in complement medicine with first new class in 15 years
- None.
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET.
To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Neil Carnahan
neil.carnahan@apellis.com
207.318.4494
FAQ
When is Apellis Pharmaceuticals (APLS) Q1 2025 earnings call?
How can investors access Apellis Pharmaceuticals (APLS) Q1 2025 earnings call?
How long will Apellis Pharmaceuticals (APLS) Q1 2025 earnings webcast be available?
What is Apellis Pharmaceuticals' (APLS) main medical breakthrough?
What therapeutic area does Apellis Pharmaceuticals (APLS) focus on?
